Weizhi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weizhi Wang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Zekuan Xu
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
3 shared publications - Zhengdong Zhang
Department of Environmental Genomics, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing 211166, China
2 shared publications - Biao Zhang
School of Economics, Fuyang Normal University, Fuyang 236037, China
1 shared publication Bowen Li
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication- Bowen Li
Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China
1 shared publication Changchun Qiu
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Schoolof Basic Medicine, Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 16
Quantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer
Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
- 1 January 2022
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 16
Open AccessQuantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer
Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
- Open Access
- 22 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (21) , eaay5525
Remote modulation of lncRNA GCLET by risk variant at 16p13 underlying genetic susceptibility to gastric cancer
The biological effects of susceptibility loci are rarely reported in gastric tumorigenesis. We conducted a large-scale cross-ancestry genetic study in 18,852 individuals and identified the potential causal variant rs3850997 T>G at 16p13 significantly associated with a decreased risk of gastric cancer [odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.83 to 0.91, P = 2.13 × 10−9]. This risk effect was mediated through the mapped long noncoding RNA GCLET (Gastric Cancer Low-Expressed Transcript; ORindirect = 0.987, 95% CI = 0.975 to 0.999, P = 0.018). Mechanistically, rs3850997 exerted an allele-specific long-range regulatory effect on GCLET by affecting the binding affinity of CTCF. Furthermore, GCLET increased FOXP2 expression by competing with miR-27a-3p, and this regulation remarkably affected in vitro, in vivo, and clinical gastric cancer phenotypes. The findings highlight the genetic functions and implications for the etiology and pathology of cancers.
- 22 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (21) , eaay5525
Open AccessRemote modulation of lncRNA GCLET by risk variant at 16p13 underlying genetic susceptibility to gastric cancer
The biological effects of susceptibility loci are rarely reported in gastric tumorigenesis. We conducted a large-scale cross-ancestry genetic study in 18,852 individuals and identified the potential causal variant rs3850997 T>G at 16p13 significantly associated with a decreased risk of gastric cancer [odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.83 to 0.91, P = 2.13 × 10−9]. This risk effect was mediated through the mapped long noncoding RNA GCLET (Gastric Cancer Low-Expressed Transcript; ORindirect = 0.987, 95% CI = 0.975 to 0.999, P = 0.018). Mechanistically, rs3850997 exerted an allele-specific long-range regulatory effect on GCLET by affecting the binding affinity of CTCF. Furthermore, GCLET increased FOXP2 expression by competing with miR-27a-3p, and this regulation remarkably affected in vitro, in vivo, and clinical gastric cancer phenotypes. The findings highlight the genetic functions and implications for the etiology and pathology of cancers.
- Open Access
- 1 January 2019
- Published by Turkish Neurosurgical Society in Turkish Neurosurgery
- Vol. 29 (6) , 811-815
Clinical study of ultrasound-guided methylene blue thoracic paravertebral nerve block for the treatment of postherpetic neuralgia
To investigate the effect of ultrasound-guided methylene blue (MB) thoracic paravertebral nerve block (TPVB) on the treatment of postherpetic neuralgia (PHN). A total of 27 patients with PHN were treated with ultrasound-guided TPVB. The blocking drug used was an MB compound preparation, and several indexes were recorded, including pain visual analogue scores (VAS), dosage of oral analgesic required, plasma interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and cortisol levels, basic viability, selfassessment, and satisfaction. The patients' VAS after TPVB were significantly reduced when compared to those before blocking. Furthermore, dosage of oral analgesic required, levels of plasma IL-6, TNF-α, and cortisol were reduced, and basic viability and self-assessments were significantly improved (p < 0.05). The treatment method was effective, did not cause any adverse effects, and patients reported higher degrees of satisfaction. Ultrasound-guided TPVB exerts significant effects on PHN. The patients' degree of pain and dosage of oral analgesic required were reduced, basic patient viability was improved, and patients reported higher degrees of satisfaction.
- 1 January 2019
- Published by Turkish Neurosurgical Society in Turkish Neurosurgery
- Vol. 29 (6) , 811-815
Open AccessClinical study of ultrasound-guided methylene blue thoracic paravertebral nerve block for the treatment of postherpetic neuralgia
To investigate the effect of ultrasound-guided methylene blue (MB) thoracic paravertebral nerve block (TPVB) on the treatment of postherpetic neuralgia (PHN). A total of 27 patients with PHN were treated with ultrasound-guided TPVB. The blocking drug used was an MB compound preparation, and several indexes were recorded, including pain visual analogue scores (VAS), dosage of oral analgesic required, plasma interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and cortisol levels, basic viability, selfassessment, and satisfaction. The patients' VAS after TPVB were significantly reduced when compared to those before blocking. Furthermore, dosage of oral analgesic required, levels of plasma IL-6, TNF-α, and cortisol were reduced, and basic viability and self-assessments were significantly improved (p < 0.05). The treatment method was effective, did not cause any adverse effects, and patients reported higher degrees of satisfaction. Ultrasound-guided TPVB exerts significant effects on PHN. The patients' degree of pain and dosage of oral analgesic required were reduced, basic patient viability was improved, and patients reported higher degrees of satisfaction.
- 1 December 2018
- Published by Elsevier in Surgical Oncology
- Vol. 27 (4) , 737-742
Comparison of treatment outcomes between laparoscopic and endoscopic surgeries for relatively small gastric gastrointestinal stromal tumors
- 1 December 2018
- Published by Elsevier in Surgical Oncology
- Vol. 27 (4) , 737-742
Comparison of treatment outcomes between laparoscopic and endoscopic surgeries for relatively small gastric gastrointestinal stromal tumors
- 6 December 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (9) , 1805-1816
A functional polymorphism in TFF1 promoter is associated with the risk and prognosis of gastric cancer
Trefoil Factor 1 (TFF1, also named pS2), which serves as the gastrointestinal mucosal protector, is known as gastric‐specific tumor suppressor gene. However, the genetic variants of TFF1 are still not well studied. In our study, we aim to explore the effects of tagging single nucleotide polymorphisms (tagSNPs) of TFF1 on risk and prognosis of gastric cancer. Seven tagSNPs of TFF1 gene were first analyzed in the discovery set, which was consisted of 753 cases and 950 cancer‐free controls. Then, the validation set (940 cases and 1,042 controls) was used for further evaluation. Moreover, we also tested the relation between these tagSNPs and prognosis of gastric cancer (GC). A series of experiments were performed to investigate the underlying mechanisms. We found that rs3761376 AA in the promoter region of TFF1, could reduce the expression of TFF1 by affecting the binding affinity of estrogen receptor 1 (ESR1, ERα), and thereby increased the risk of GC (1.29, 1.08–1.53). Moreover, the rs3761376 AA genotype was also found associated with worse prognosis among patients receiving 5‐FU based chemotherapy after surgery (1.71, 1.18–2.48). Further functional assays demonstrated that TFF1 could increase the chemosensitivity of 5‐FU by modulating NF‐κB targeted genes. These results identified the effect of rs3761376 on TFF1 expression, which accounted for the correlation with susceptibility and prognosis of GC; and this genetic variant may be a potential biomarker to predict the risk and survival of GC.
- 6 December 2017
- Published by Wiley in International Journal of Cancer
- Vol. 142 (9) , 1805-1816
A functional polymorphism in TFF1 promoter is associated with the risk and prognosis of gastric cancer
Trefoil Factor 1 (TFF1, also named pS2), which serves as the gastrointestinal mucosal protector, is known as gastric‐specific tumor suppressor gene. However, the genetic variants of TFF1 are still not well studied. In our study, we aim to explore the effects of tagging single nucleotide polymorphisms (tagSNPs) of TFF1 on risk and prognosis of gastric cancer. Seven tagSNPs of TFF1 gene were first analyzed in the discovery set, which was consisted of 753 cases and 950 cancer‐free controls. Then, the validation set (940 cases and 1,042 controls) was used for further evaluation. Moreover, we also tested the relation between these tagSNPs and prognosis of gastric cancer (GC). A series of experiments were performed to investigate the underlying mechanisms. We found that rs3761376 AA in the promoter region of TFF1, could reduce the expression of TFF1 by affecting the binding affinity of estrogen receptor 1 (ESR1, ERα), and thereby increased the risk of GC (1.29, 1.08–1.53). Moreover, the rs3761376 AA genotype was also found associated with worse prognosis among patients receiving 5‐FU based chemotherapy after surgery (1.71, 1.18–2.48). Further functional assays demonstrated that TFF1 could increase the chemosensitivity of 5‐FU by modulating NF‐κB targeted genes. These results identified the effect of rs3761376 on TFF1 expression, which accounted for the correlation with susceptibility and prognosis of GC; and this genetic variant may be a potential biomarker to predict the risk and survival of GC.
- 1 January 2015
- Published by Elsevier in International Journal of Cardiology
- Vol. 179, 558-560
Prevalence of conventional cardiovascular disease risk factors among Chinese Kazakh individuals of diverse occupational backgrounds in Xinjiang China
- 1 January 2015
- Published by Elsevier in International Journal of Cardiology
- Vol. 179, 558-560
Prevalence of conventional cardiovascular disease risk factors among Chinese Kazakh individuals of diverse occupational backgrounds in Xinjiang China
- 1 December 2012
- Published by Elsevier in Epilepsy & Behavior
- Vol. 25 (4) , 695-699
Clinical features of paroxysmal kinesigenic dyskinesia: Report of 24 cases
- 1 December 2012
- Published by Elsevier in Epilepsy & Behavior
- Vol. 25 (4) , 695-699
Clinical features of paroxysmal kinesigenic dyskinesia: Report of 24 cases